You are here

FDA Approves Schizophrenia Treatment Aristada

Long-acting injectable offers dosing once every four or six weeks

Aripiprazole lauroxil (Artistada, Alkermes) is an extended-release injectable suspension approved for the treatment of schizophrenia. It is the first atypical antipsychotic with once-monthly and once-every-six-weeks dosing options.

FDA approval was partly based on data from a phase 3 study in which multiple dosing strengths of aripiprazole lauroxil met the primary endpoint with statistically significant and clinically meaningful reductions in positive and negative syndrome scale (PANSS) total scores at week 12and demonstrated significant improvements in schizophrenia symptoms compared with placebo. The most common adverse events were insomnia, akathisia, and headache. The study was published in the June 2015 issue of the Journal of Clinical Psychiatry.

According to Alkermes, the range of dose strengths and dosing-interval options with  aripiprazole lauroxil are designed to address the individual needs of patients and the challenges in treatingschizophrenia. Long-acting injectable antipsychotics provide patients with blood concentrations of active drug that remain within a therapeutic range for an extended period and help health care providers track patient adherence.

According to BloombergBusiness, the drug will cost approximately $1,500 a month. The cost for an individual patient would depend on the dose and would be comparable to already approved schizophrenia drugs, such as Johnson & Johnson’s Risperdal (risperidone) and Invega (paliperidone), Alkermes said.

Sources: Alkermes, October 5, 2015; and BloombergBusiness, October 5, 2015.

Recent Headlines

Citrus, Berries, Broccoli Reduce Risk of Cancer and CVD
Changes in Antibiotic Recommendations for Children
Influences Gene Involved in Circadian Rhythms
‘The Perfect Drug for Trauma-Focused Psychotherapy’
Triggers the Body’s Own Natural Blood Flow Regulation
Inrebic Reduces Symptoms by 50% in Some Patients
Novel Catheter-based Technology for Treating Acute Ischemic Stroke
Decision supported by data from more than 4,000 patients